Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-05-31
2011-05-31
Cordero Garcia, Marcela M (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S085500, C424S085700, C424S130100, C424S230100
Reexamination Certificate
active
07951770
ABSTRACT:
Disclosed are compositions and methods for modulating Epstein-Barr virus (EBV) infection in a patient. The compositions may include peptides or peptidomimetics that are related to gp42 and function to inhibit EBV-mediated membrane fusion.
REFERENCES:
patent: 5817647 (1998-10-01), Casara et al.
patent: 6608110 (2003-08-01), Stamler et al.
patent: WO 9530015 (1995-11-01), None
Nalesnik et al. The Pathology of Posttransplant Lymphoproliferative Disorders Occurring in the Setting of Cyclosporin A-Prednisone Immunosuppression. American Journal of Pathology, 1988. vol. 133, Nol. 1. pages 173-192.
Haan, Keith M. et al, “Coreceptor Restriction Within the HLA-DQ Locus for Epstein-Barr Virus Infection”, PNAS, Aug. 1, 2000, vol. 97, No. 16, pp. 9252-9257.
Mullen, Maureen M. et al, “Structure of the Epstein-Barr Virus gp42 Protein Bound to the MHC Class II Receptor HLA-DR1”, Molecular Cell, Feb. 2002, vol. 9, pp. 375-385.
McShane, Marisa P. et al, “Mutational Analysis of the HLA Class II Interaction with Epstein-Barr Virus Glycoprotein 42”, Journal of Virology, Jul. 2003, vol. 77, No. 13, pp. 7655-7662.
Ressing, Maaike E. et al, “Interference with T Cell Receptor-HLA-DR Interactions by Epstein-Barr Virus gp42 Results in Reduced T Helper Cell Recognition”, PNAS, Sep. 30, 2003, vol. 100, No. 20, pp. 11583-11588.
Silva, Amanda L. et al, “Mutational Analyses of Epstein-Barr Virus Glycoprotein 42 Reveal Functional Domains Not Involved in Receptor Binding but Required for Membrane Fusion”, Journal of Virology, Jun. 2004, vol. 78, No. 11, pp. 5946-5956.
Kirschner, Austin N. et al, “Soluble Epstein-Barr Virus Glycoproteins gH, gL, and gp42 Form a 1:1:1 Stable Complex That Acts Like Soluble gp42 in B-Cell Fusion but Not in Epithelial Cell Fusion”, Journal of Virology, Oct. 2006, vol. 80, No. 19, pp. 9444-9454.
Kirschner, Austin N. et al, “Binding-Site Interactions Between Epstein-Barr Virus Fusion Proteins gp42 and gH/gL Reveal a Peptide That Inhibits Both Epithelial and B-Cell Membrane Fusion”, Journal of Virology, Sep. 2007, vol. 81, No. 17, pp. 9216-9229.
Omerovic, Jasmina et al, “The Amino Terminus of Epstein-Barr Virus Glycoprotein gH is Important for Fusion with Epithelial and B Cells”, Journal of Virology, Oct. 2005, vol. 79, No. 19, pp. 12408-12415.
McShane, Marisa P. et al, “Cell-Surface Expression of a Mutated Epstein-Barr Virus Glycoprotein B Allows Fusion Independent of Other Viral Proteins”, PNAS, Dec. 14, 2004, vol. 101, No. 50, pp. 17474-17479.
Wu, Liguo et al, “Point Mutations in EBV gH That Abrogate or Differentially Affect B Cell and Epithelial Cell Fusion”, NIH Public Access, Author Manuscript (pp. 1-17), published in final edited form as: Virology, Jun. 20, 2007, 363(1): 148-155.
Shannon-Lowe, C. D. et al, “Resting B Cells as a Transfer Vehicle for Epstein-Barr Virus Infection of Epithelial Cells”, PNAS, May 2, 2006, vol. 103, No. 18, pp. 7065-7070.
Wu, Liguo et al, “Mutations of Epstein-Barr Virus gH That Are Differentially Able to Support Fusion with B Cells or Epithelial Cells”, Journal of Virology, Sep. 2005, vol. 79, No. 17, pp. 10923-10930.
Ressing, Maaike E. et al, “Epstein-Barr Virus gp42 is Posttranslationally Modified to Produce Soluble gp42 That Mediates HLA Class II Immune Evasion”, Journal of Virology, Jan. 2005, vol. 79, No. 2, pp. 841-852.
Johannsen, Eric et al, “Proteins of Purified Epstein-Barr Virus”, PNAS, Nov. 16, 2004, vol. 101, No. 46, pp. 16286-16291.
Guerreiro-Cacais, Andre Ortlieb et al, “Capacity of Epstein-Barr Virus to Infect Monocytes and Inhibit Their Development Into Dendritic Cells is Affected by the Cell Type Supporting Virus Replication”, Journal of General Virology (2004), 85, pp. 2767-2778.
Borza, Corina M. et al, “Use of gHgL for Attachment of Epstein-Barr Virus to Epithelial Cells Compromises Infection”, Journal of Virology, May 2004, vol. 78, No. 10, pp. 5007-5014.
Li, Qingxue et al, “The Epstein-Barr Virus (EBV) BZLF2 Gene Product Associates with the gH and gL Homologs of EBV and Carries an Epitope Critical to Infection of B Cells but Not of Epithelial Cells”, Journal of Virology, Jul. 1995, vol. 69, No. 7, pp. 3987-3994.
Wang, Xi et al, “Epstein-Barr Virus Uses Different Complexes of Glycoproteins gH and gL to Infect B Lymphocytes and Epithelial Cells”, Journal of Virology, Jul. 1998, vol. 72, No. 7, pp. 5552-5558.
Li, Qingxue et al, “Epstein-Barr Virus Uses HLA Class II as a Cofactor for Infection of B Lymphocytes”, Journal of Virology, Jun. 1997, vol. 71, No. 6, pp. 4657-4662.
Molesworth, Sara J. et al, “Epstein-Barr Virus gH is Essential for Penetration of B Cells but Also Plays a Role in Attachment of Virus to Epithelial Cells”, Journal of Virology, Jul. 2000, vol. 74, No. 14, pp. 6324-6332.
Spear, Patricia G. et al, “Herpesvirus Entry: An Update”, Journal of Virology, Oct. 2003, vol. 77, No. 19, pp. 10179-10185.
Haan, Keith M. et al, “Different Functional Domains in the Cytoplasmic Tail of Glycoprotein B Are Involved in Epstein-Barr Virus-Induced Membrane Fusion”, Virology, 290, 106-114 (2001).
Oda, Takanori et al, “Epstein-Barr Virus Lacking Glycoprotein gp85 Cannot Infect B Cells and Epithelial Cells”, Virology, 276, 52-58 (2000).
Speck, Peter et al, “Epstein-Barr Virus Entry Into Cells”, Virology, 277, 1-5 (2000).
Jardetzky Theodore S.
Kirschner Austin N.
Longnecker Richard
Omerovic Jasmina
Andrus Sceales Starke & Sawall LLP
Cordero Garcia Marcela M
Northwestern University
LandOfFree
Peptides, peptidomimetics and small molecule inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides, peptidomimetics and small molecule inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides, peptidomimetics and small molecule inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2651908